Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 14/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23206123 | 0.80 | METAP2 (0.47) | METAP2CYP1A2AXLIDO1TRPA1 | |
| SCHEMBL20327308 | 0.78 | IDO1 (0.43) | METAP2CYP1A2AXLIDO1TRPA1 | |
| SCHEMBL20974448 | 0.78 | METAP2 (0.45) | METAP2CYP1A2AXLIDO1TRPA1 | |
| SCHEMBL29937247 | 0.78 | METAP2 (0.45) | METAP2CYP1A2AXLIDO1TRPA1 | |
| SCHEMBL21216223 | 0.76 | IDO1 (0.41) | METAP2CYP1A2IDO1TLR9TLR8 | |
| SCHEMBL29344861 | 0.75 | METAP2 (0.43) | METAP2CYP1A2AXLIDO1TRPA1 | |
| SCHEMBL12110234 | 0.75 | METAP2 (0.46) | METAP2AXLIDO1TRPA1TLR9 | |
| SCHEMBL23588717 | 0.74 | METAP2 (0.40) | METAP2CYP1A2IDO1TLR9TLR8 | |
| SCHEMBL24175930 | 0.73 | AXL (0.54) | METAP2CYP1A2AXLIDO1TRPA1 | |
| SCHEMBL21216222 | 0.73 | METAP2 (0.39) | METAP2CYP1A2IDO1TRPA1TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | METAP2 3168/4885CYP1A2 4576/4885AXL 2654/4885 |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | METAP2 3905/4885CYP1A2 3378/4885AXL 1986/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | METAP2 3204/4885CYP1A2 3478/4885AXL 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.